Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential

1Immune homeostasis refers to the immune system’s ability to maintain balance and stability, ensuring proper function under normal physiological conditions and during immune responses. Foxp3, the key transcription factor of Treg cells, governs their function by modulating the expression of specific genes, either activating or repressing targets.– As essential regulators of immune balance, Foxp3⁺ Tregs contribute to self-tolerance and immune homeostasis., An imbalance in Treg activity or numbers can have significant consequences: excessive Treg activity or abundance may result in immunodeficiency, chronic infections, and cancer, whereas insufficient Treg activity or numbers may induce autoimmunity, immunopathology, and compromised pathogen-specific immune responses. Notably, Tregs exhibit exceptional plasticity, enabling them to adapt to their microenvironment and enhancing their suppressive functions. However, under inflammatory conditions, these cells may differentiate into effector cells, such as Th1 or Th17 cells. Tregs not only suppress T cells but also modulate B cells, natural killer (NK) cells, and nonlymphoid cells, such as those in adipose tissue.,, Exploring Treg metabolism can provide insights into targeted therapeutic strategies.

2Treg cell targeting has become a promising approach for modulating immune responses, restoring balance, and treating various diseases. These cells are crucial for preserving immune stability by modulating excessive immune responses and safeguarding against autoimmunity. Given their central role in immune regulation, Treg-targeted therapies have been widely applied across multiple diseases, notably in cancer immunotherapy, where Tregs serve as key immunosuppressive factors by inhibiting antitumor immunity, promoting tumor progression, and reducing therapeutic efficacy.– Current targeting strategies include monoclonal antibodies, small-molecule inhibitors, bispecific antibodies, and cell-based therapies, such as engineered TCR-Tregs and CAR-Tregs. While these approaches show significant promise, they also face challenges, such as achieving selective targeting of tumor-infiltrating Tregs (TI-Tregs), minimizing the risk of autoimmunity, and addressing Treg heterogeneity and plasticity. Among these strategies, cell-based therapies have gained particular attention, with engineered CAR-Tregs demonstrating remarkable efficacy in disease models, including transplantation,, autoimmune disorders, and graft-versus-host disease (GVHD). Clinical trials involving patients with type 1 diabetes, and GVHD,, have provided preliminary evidence supporting the feasibility, safety, and efficacy of Treg-based therapies. Moving forward, deepening our understanding of Treg biology, including their metabolic states and epigenetic regulation, optimizing targeting strategies, and developing precise regulatory tools will pave the way for expanding the clinical applications of Treg-targeted therapies across a wide range of disease settings. This review explores the functions and characteristics of Treg cells, as well as their roles in various diseases and therapeutic approaches, including cancer, neurodegenerative disorders, autoinflammatory and autoimmune diseases, and transplantation.

3In the early 1970s, researchers first identified a subset of T cells with immunosuppressive properties.– Specifically, in 1995, Sakaguchi et al. reported that CD25 (IL-2 receptor subunit-α) was a phenotypic marker of mouse suppressive CD4+ T cells and proposed the concept of Treg cells. Later, this type of suppressive T cell was also identified in the human CD4+CD25high T cell population.– In 2003, Foxp3, a forkhead/winged-helix transcription factor specifically expressed in Tregs, was subsequently identified as a lineage-defining factor in mouse,, and human Tregs,, thus establishing CD4+CD25+Foxp3+ cells as a defining feature of Tregs. In the same year, scientists reported that transforming growth factor (TGF)-β can induce naive CD4+ cells to differentiate into Treg cells and inhibit the activity of conventional T cells in vitro. Since 2010, researchers have explored the characteristics of Tregs and the role of Foxp3 in treating diseases. Extensive preclinical studies have demonstrated the critical role of Tregs in preventing GVHD,,, autoimmune diseases,, transplant rejection,,, tumors,, and even neurodegenerative diseases., These studies have yielded positive results and provided a theoretical basis for the therapeutic application of Tregs. The first clinical trial of adoptive transfer of Tregs in patients with GVHD was published in 2009. In 2011 and 2012, researchers conducted human clinical studies on the adoptive transfer of Treg cells in patients with stem cell transplantation and Crohn’s disease. The first clinical use of Tregs for type 1 diabetes treatment was reported in 2014, which demonstrated that ex vivo expanded autologous Tregs were safe for patients. Additionally, research has indicated that Treg depletion or transplantation of in vitro-depleted Treg suspensions into T cell-deficient mice effectively suppresses tumor growth. More recently, Deepali et al. reported that IL-10 and IL-35 from Treg cells in the tumor microenvironment (TME) promote CD8+ T cell exhaustion, and that their deletion reduces tumor growth. Targeting JMJD1C or p97–Npl4 disrupts tumor Treg cells, increasing antitumor immunity. Advances in cell encapsulation and microneedle technologies offer novel delivery systems for Tregs, protecting them from immune rejection and enhancing their efficacy (Fig. 1).

4Treg cells exhibit substantial heterogeneity and can be classified according to their origin, activation status, tissue-specific localization, and recent insights from single-cell sequencing technologies. Traditionally, Tregs are categorized based on their developmental origin into three main Treg populations: (1) the majority of Foxp3+ Tregs are generated in the thymus and are referred to as thymus-derived Tregs (tTregs); (2) in the periphery, a certain proportion of Tregs can be derived from Foxp3− T conventional (Tconv) cells, and this population is known as peripherally derived Tregs (pTregs); and (3) when Tconv cells are stimulated in vitro with TGF-β, they differentiate into Foxp3⁺ T cells, known as in vitro-induced Tregs (iTregs). Early studies identified Helios and Neuropilin-1 (NRP1), as tTreg cell markers, but they were subsequently identified in pTreg cells. Recently, GPA33 was shown to be a reliable marker for human tTregs. tTregs exhibit a stable regulatory phenotype characterized by full demethylation of the Treg-specific demethylated region (TSDR), ensuring long-term immunosuppressive function. In contrast, pTregs show partial TSDR demethylation, potentially making them less stable and more susceptible to conversion into effector T cells under certain conditions. Moreover, iTregs retain a fully methylated TSDR, indicating their transient and less stable regulatory nature., In addition to origin-based subsets, Tregs can also be distinguished based on their activation status. Human naive or resting Tregs (rTreg) typically express CD45RA and relatively low levels of Foxp3 (CD45RA⁺Foxp3lo). Upon activation, they transition to an activated state characterized by CD45RO expression along with elevated levels of Foxp3, inducible co-stimulator (ICOS), and cytotoxic T lymphocyte antigen-4 (CTLA-4), and acquire enhanced suppressive functions.– Similarly, in mice, naive (resting) Tregs possess a CD44loCD62L⁺ phenotype and primarily reside in lymphoid tissues. Activated Tregs (aTregs), which are characterized by CD44hiCD62L⁻ along with high ICOS and CTLA-4 expression, migrate to sites of inflammation to exert potent immunosuppressive effects., Recent research has further revealed the existence of specialized tissue-specific Treg subsets adapted uniquely to their anatomical niches. Adipose tissue-resident Tregs express distinct markers, such as peroxisome proliferator-activated receptor (PPARγ) and ST2 (the receptor for IL-33), which play critical roles in regulating adipose tissue inflammation and metabolic homeostasis., Intestine-resident Tregs frequently coexpress RAR-related orphan receptor γt (RORγt), which is essential for maintaining intestinal mucosal tolerance., Tumor-infiltrating Tregs typically express high levels of ICOS, PD-1, and CCR8, significantly contributing to immune evasion and tumor progression., Additionally, skin-resident Tregs express homing markers such as cutaneous lymphocyte antigen (CLA) and CCR4,, whereas central nervous system (CNS)-resident Tregs produce amphiregulin and express CD103, supporting tissue repair functions.,

5Recent advances in single-cell RNA sequencing (scRNA-seq) have provided new insights into the classification of novel Treg subsets with high resolution.– Using scRNA-seq, six Treg clusters have been identified in healthy peripheral blood, whereas other studies suggest further subdivision into nine clusters. Furthermore, scRNA-seq analysis revealed that T cell receptor (TCR) signal strength does not affect the proportions of resting/activated Tregs. However, TCR signals unexpectedly shape the diverse functional states of activated Tregs. Additionally, Treg cells exhibit transcriptional flexibility, adapting to different tissue environments while preserving core expression programs across homeostasis, disease, and species. Trajectory analyses revealed two Treg differentiation paths (I/II) with distinct phenotypic and functional programs, culminating in the Foxp3hi and MKI67hi subsets, driven by transcription factors such as Foxp3 and SUB1, respectively. These findings provide a single-cell atlas for exploring Treg complexity in health and disease. These single-cell insights emphasize the complexity of Treg biology, underscoring the diversity of Treg functional states, which were previously unrecognized via traditional methods.

6Treg-expressed molecules are categorized as intracellular (Foxp3, Helios) and extracellular (CD304, CD25, CD39, CD73, CD62L, CD103, CD134, FR4, CD127⁻, CD152, CD279, GITR, CD223, TIGIT) (Table 1). Foxp3 and Helios are key intracellular markers of Tregs. Foxp3, a crucial transcription factor, drives the differentiation of naive CD4⁺ T cells into Tregs and is essential for their suppressive function., Helios, a member of the Ikaros zinc finger protein family, is expressed predominantly in tTregs., CD304 (NRP-1), a transmembrane protein, is highly expressed on tTregs., Therefore, Helios and NRP1 are often used to separate tTreg cells from pTreg cells in certain physiological settings. CD25, the alpha chain of the IL-2 receptor, plays a key role in the activation and proliferation of immune cells. It is widely used to identify Treg cells and has therapeutic significance in both immunosuppressive and activating settings., CD39 and CD73, two ectonucleases abundantly expressed on Tregs, serve as key markers for this T cell subset., These ectonucleases are essential for adenosine production in Treg cells, as they work together to generate extracellular adenosine through ATP hydrolysis, promoting an immunosuppressive microenvironment., CD62L, a selectin molecule, facilitates the homing of immune cells to lymphoid tissues., Treg cells support their migration to secondary lymphoid organs. Like CD62L, CD103 (αEβ7 integrin) is an adhesion molecule essential for mucosal immunity that facilitates lymphocyte adhesion, graft rejection, and gut-homing effector cell generation. It plays a crucial role in retaining Tregs at inflammatory sites. CD134 (OX40) is a costimulatory receptor that is transiently expressed on effector T cells after TCR activation and promotes their proliferation and memory formation. Additionally, OX40 costimulates Tregs, reducing their suppressive function and Foxp3 expression., The ability of OX40 to activate T cells while limiting Treg suppression makes OX40 a key therapeutic target in cancer and autoimmunity. Folic acid receptor 4 (FR4) is expressed at high levels in TGF-β-induced Tregs and tTregs and plays a crucial role in sustaining Treg proliferation., CD127low, along with Foxp3 and CD25, serve as identification markers for Tregs, which are characterized as Foxp3+CD25+CD127low., CD152 (CTLA-4), CD279 (PD-1) and GITR are immune checkpoint molecules highly expressed on Tregs, where they engage their respective ligands on effector T cells to mediate immunosuppression. These two molecules help Tregs maintain tolerance by preventing overactive immune responses but also enable tumors to evade immunity through enhanced Treg-mediated suppression.– CD223 (LAG-3) and TIGIT are immune checkpoint molecules, such as PD-1 and CTLA-4, but they have distinct functions, particularly in different tissue sites where they regulate various aspects of immunity. Many patients continue to show limited response to therapies targeting CTLA-4 and PD-1, driving the exploration of LAG-3 and TIGIT as the next generation of coinhibitory receptor targets in clinical trials., The specific functions of these inhibitory checkpoint molecules are discussed in detail in the section on immunotherapy strategies targeting Tregs in human diseases.

7Treg cell stability refers to the capacity of regulatory T cells to sustain Foxp3 expression under inflammatory stress while preventing their conversion into pro-inflammatory effector cells. In simpler terms, it refers to their capacity to remain as Foxp3+ Treg cells and avoid transitioning into Foxp3⁻ ex-Treg cells.– This stability is a complex phenomenon governed by metabolic programs, epigenetic modifications, and transcriptional regulation. This stability is crucial for the ability of Tregs to perform their immunosuppressive functions effectively. Recent studies have highlighted the intricate regulation of Treg cell stability by metabolic programs.– Metabolic pathways, including glycolytic flux, fatty acid β-oxidation (FAO), and amino acid catabolism, are essential for maintaining Treg cell stability. In addition to metabolic regulation, epigenetic mechanisms critically govern Treg cell stability.– Epigenetic modifications, specifically DNA methylation and histone acetylation, play pivotal roles in stabilizing the Treg phenotype. These modifications act as molecular switches, turning genes on or off that are critical for Treg function. For instance, stable Treg cells tend to have demethylated Foxp3 loci, whereas unstable Treg cells may exhibit methylation changes that compromise Foxp3 expression. Tregs maintain their identity and suppressive capabilities in a dynamic immune environment by regulating gene expression at the epigenetic level (Fig. 2a).

8Transcriptional regulation is another cornerstone of Treg stability., Key transcription factors, such as NFAT, STAT5, and Runx, orchestrate the expression of Foxp3 and other Treg-specific genes, such as IL-2RA and IL-10., These transcription factors synergistically assemble, binding to the promoters and enhancers of Treg-specific genes to ensure the robust expression of the Treg gene signature. For instance, NFAT is reactivated by calcium signaling to induce Foxp3 expression, thereby promoting Treg cell differentiation. In contrast, STAT5 is activated downstream of cytokine receptors, such as IL-2R, and is indispensable for Treg cell survival and proliferation. Additionally, these transcription factors regulate other genes crucial for Treg function, including those encoding negative immune cytokine superfamily members such as IL-10 and TGF-β (Fig. 2b). The elaborate transcriptional network governed by these factors mediates the distinctive transcriptional profile of Treg cells, which underpins their suppressive capacity and stability. Conserved noncoding sequences (CNS0–CNS3) within the Foxp3 locus recruit transcription factors to regulate Foxp3 expression.,, In Treg cells, CNS0 serves as a binding platform for the STAT5 transcription factor in the IL-2Rβ/JAK3–STAT5 signaling axis, thereby promoting the differentiation of thymic precursor cells into Tregs. The CNS1 element contains the TGF-β–NFAT response element,, whereas the CNS2 element, also known as the TSDR, is enriched with CpG motifs, whose demethylation is critical for maintaining Foxp3 stability.,,– Runx–CBFβ complexes are required for maintaining Treg stability by binding to the CNS2 locus of Foxp3., c-Rel binding to CNS3 enhances Treg production in the thymus and periphery. Additionally, CNS3 cooperates with CNS0 to initiate and stabilize Foxp3 expression, regulating Treg development, maintenance, and self-tolerance.,

9The functional adaptability of regulatory T cells manifests as their capacity to undergo ‌transcriptional reprogramming‌, mimicking effector T lymphocyte differentiation pathways, thereby generating T helper lineage-mimicking Treg clusters‌ with ‌stable Foxp3 maintenance‌. This adaptation allows Tregs to exert targeted immunosuppressive functions in response to specific inflammatory signals and environmental conditions., Several Th-like Treg subsets have been identified, including type 1 Tregs (Tr1), which are defined by the co-expression of T-BET, CXCR3, and Foxp3; Th2-skewed Tregs (Gata3+IRF4+IL4+Foxp3+); RORγt+ Tregs, which are characterized by the dual expression of IL-17A and Foxp3; and follicular Tregs (Tfr-like Tregs) (BCL6+Foxp3+) (Fig. 3).,– Th1-like Tregs produce IFN-γ and upregulate Th1-associated markers, including T-BET and CXCR3. Their induction is driven by factors such as IL-12, IFN-γ, and IL-27., Th2-like Tregs with elevated IL-4, GATA3, and IRF4 expression appear under pathological conditions. They effectively suppress Th1 and Th17 responses,– and exhibit greater migratory capacity, enabling rapid accumulation at tumor sites, where they contribute to a tumor-promoting environment. Th17-like Tregs express IL-17, IL-22, IL-23R, and RORγt,, and are found primarily in the intestines of humans, and mice. While their exact role remains unclear, these cells may be pathogenic, contributing to inflammatory bowel disease (IBD) and colon cancer. Tfr-like Tregs, characterized by BCL6 and Foxp3 co-expression, specialize in regulating follicular responses within germinal centers (GCs) and maintaining immune tolerance and B cell homeostasis.,

10Cellular metabolism is essential for regulating various aspects of Treg cells, including their stability, function and differentiation. The key metabolic signaling pathways involved include nutrient uptake, glycolysis, mitochondrial metabolism, and lipid and fatty acid metabolism (Fig. 4). Notably, immune receptors and metabolism-related environmental signals, such as nutrients, interact extensively to mediate immune responses in vivo., Among these metabolic regulators, all-trans retinoic acid (RA), a vitamin A derivative, promotes iTreg differentiation by enhancing TGF-β signaling through the ERK1/2 pathway. Similarly, vitamin C facilitates the demethylation of the CpG motif in Foxp3 CNS2 through ten-eleven translocation (TET2), promoting stable Foxp3 expression., Additionally, 1,25-dihydroxyvitamin D₃ (1,25(OH)₂D₃) enhances Foxp3 expression by binding to the vitamin D response element (VDRE) within the CNS region of the human Foxp3 gene.– Tregs depend primarily on lipid oxidative phosphorylation (OXPHOS), similar to memory T cells, in contrast to the glycolytic preference observed in effector T cells.,– Fatty acid binding protein 5 (FABP5) is a member of the lipid chaperone family. Inhibition of FABP5 in Tregs induces mitochondrial DNA (mtDNA) release, activating the cGAS-STING signaling pathway. This pathway boosts IL-10 and IFNA4 production and reinforces the suppressive function of Tregs. Stearoyl-CoA desaturase 1 (SCD1) is the rate-limiting enzyme in oleic acid synthesis during fatty acid metabolism. SCD1 or oleic acid deficiency elevates H3K79me2 at the ATP2A2 locus, increasing ATP2A2 expression. This activation enhances the calcium–calcineurin–NFAT axis, driving Tconvs differentiation into Tregs in the mouse thymus. CD36, a scavenger receptor, plays a key role in long-chain fatty acid absorption and lipid metabolism. The activation of peroxisome proliferator-activated receptor gamma (PPARγ) increases the frequency of Treg cells by increasing CD36/carnitine palmitoyltransferase-1 (CPT-1)-driven FAO and the subsequent N-glycosylation of TβRII/IL-2Rα, thereby promoting Treg function. In tumors, CD36 deletion in Tregs alters fatty acid metabolism, increasing IFN-γ and TNF-α production while reducing tumor infiltration. Furthermore, CD36-PPAR-β signaling regulates mitochondrial fitness and lactate metabolism, which are crucial for Treg survival. CD36 blockade via monoclonal antibodies enhances antitumor immunity, offering a strategy to reshape the TME while preserving systemic immune balance. Vacuolar protein sorting 33B (Vps33B) maintains the homeostasis of the endosome/lysosome system and regulates the activation of the amino acid signal-dependent mTORC1 pathway and cellular metabolism, thereby maintaining the suppressive function of Treg cells. Myc regulates Treg accumulation and functional activation by modulating mitochondrial oxidation, independent of FAO. Myc-deficient Tregs exhibit defective accumulation and activation, leading to autoimmune diseases accompanied by effector T cell responses. The enzyme pyruvate dehydrogenase (PDH) serves as a regulator of the tricarboxylic acid (TCA) cycle. Park7 (DJ-1) binds to PDHE1-β (PDHB) to promote PDH activity and OXPHOS. Treg-specific DJ-1 deletion reduces Treg survival in mice and reduces Treg stability and number in aged mice. Methylenetetrahydrofolate dehydrogenase-2 (MTHFD2) is a mitochondrial enzyme involved in folate metabolism. MTHFD2 deficiency enhances Treg differentiation by depleting purine pools, increasing the accumulation of purine biosynthetic intermediates, and reducing mTORC1 signaling. Moreover, the metabolism of nicotinamide adenine dinucleotide (NAD+) is linked to the regulation of Treg cell function. NAD+ levels influence the activation and function of Tregs, indicating that the modulation of NAD+ metabolism may affect Treg cell-mediated immune tolerance. Treg cells in the TME highly express the immune checkpoint receptor PD-1. Deleting or inhibiting PD-1 in Treg cells can delay tumor progression by weakening lipid metabolism and the proliferation of TI-Tregs., Additionally, in mice lacking PD-L2, pTreg-specific knockout of PD-L2 reduced the number of pTregs at steady state and their suppressive activity. Transketolase (TKT) is an essential enzyme in the pentose phosphate pathway (PPP). TKT deficiency disrupts Treg suppressive activity by causing uncontrolled OXPHOS while maintaining normal Treg cell numbers. Mitochondrial respiratory chain complex III knockout in Treg cells impairs their suppressive function without altering their cell number in mice. Mitochondria-derived reactive oxygen species (ROS) reportedly increase the stability of SUMO-specific protease 3 (SENP3) by inhibiting its ubiquitin-mediated degradation,, and triggering the deSUMOylation of the transcription factor BACH2. SENP3-mediated BACH2 deSUMOylation prevents its nuclear export, thus maintaining Treg stability and function. Glycolysis is key for Treg cell migration to inflamed tissues and is mediated by glucokinase induced by the PI3K‒mTORC2 pathway. Additionally, the PI3K–AKT–mTORC2 pathway promotes Treg migration to peripheral nonlymphoid organs while limiting lymphoid recirculation by suppressing forkhead box O 1/3 (Foxo1/3). Furthermore, hypoxia-inducible factor (HIF)-1α, a transcription factor, has been reported to increase glycolysis, induce Foxp3 expression,, and enhance the migration of Treg cells. Consistent with these reports, VHL, an E3 ubiquitin ligase, is essential for Treg stability and suppressive function through the regulation of the HIF-1α pathway. Treg cells in human tumors increase glucose consumption, promote cell senescence and suppress effector T cells, which hinder tumor immunotherapy. The activation of Toll-like receptor 8 (TLR8) impairs glucose uptake and glycolysis in Tregs, disrupting their function and enhancing antitumor immunity.

11Liver kinase B1 (LKB1) is a kinase that phosphorylates and activates AMP-activated protein kinase (AMPK), triggering metabolic adaptations to restore energy balance.– Emerging evidence suggests that LKB1 is essential for regulating Treg cell metabolism and stability. Interestingly, these events seem to occur independently of AMPK,– indicating the involvement of other downstream targets in Treg metabolic regulation. Recent studies on Tregs lacking LKB1 revealed that LKB1 maintains Foxp3 stability by inhibiting STAT4-driven methylation of CNS2 at the Foxp3 locus, and by activating the mevalonate pathway, which produces key metabolites such as cholesterol and the isoprenoid geranylgeranyl pyrophosphate (GGPP). Moreover, treatment with mevalonate or GGPP rescues the function and stability of Tregs lacking LKB1. In addition, LKB1 function in Treg cells also contributes to the activation of β-catenin signaling, regulating immune regulatory molecules such as PD-1, GITR, and OX40 to effectively suppress Th2 responses. The function of LKB1 in Tregs is driven by MAP/microtubule affinity-regulating kinases (MARKs) and salt-inducible kinases (SIKs). However, the precise mechanisms regulating LKB1 activation in Treg cells require further investigation. Amino acids support Treg cell function through TCR-induced mTORC1 activation. The RagA and RheB GTPases play key roles in amino acid-driven mTORC1 activation in Tregs. Treg-specific RagA-RagB- or Rheb1-Rheb2-knockout mice exhibit impaired amino acid metabolism, reduced Treg cell proliferation, and fatal autoimmune diseases. Notably, Tregs in peripheral tissues, especially tumors, show increased sensitivity to nutrient sensing via Rag GTPases. Selective deletion of RagA reduces Treg infiltration in tumors, thereby enhancing antitumor immune responses. Recent research has shown that the IL-33/ST2 signaling pathway plays a very important role in ST+ Treg cells. IL-33 facilitates the accumulation and maintenance of ST2+ Tregs in the intestine, thereby enhancing their protective role in intestinal inflammation. Lymphoid-derived visceral adipose tissue (VAT) Treg precursors (PPARγlow), guided by tissue-specific TCR signals via C-C motif chemokine receptor 2 (CCL2), migrate to the VAT, where IL-33 drives their local expansion and differentiation into ST2+ VAT Tregs (PPARγhi).– In individuals with inflammatory bowel disease, RORγt+ Treg cells expand and express pro-inflammatory cytokines via Wnt–β-catenin signaling, which disrupts transcription factor T cell factor 1 (TCF-1) and Foxp3 regulation of pro-inflammatory genes, promoting a disease-associated phenotype. The release of extracellular adenosine triphosphate (ATP) by dying and inflammatory cells impairs the suppressive function and stability of Tregs by activating purinergic P2X receptors. Inhibition of the extracellular ATP-P2X signaling pathway enhances Treg function in the muscle inflammatory response and slows the progression of the muscular dystrophy phenotype.–

12The molecular mechanisms regulating Foxp3 expression and function have been extensively studied. Recent studies have highlighted the critical role of Blimp1 in preserving Treg identity, particularly under inflammatory conditions. IL-6 signaling activates Dnmt3a, a DNA methylase that, in the absence of Blimp1, targets distinct DNA sites, leading to CNS2 methylation and Foxp3 downregulation. Conversely, Blimp1 suppresses Dnmt3a upregulation, preventing CNS2 methylation at the Foxp3 locus and thereby maintaining Treg stability and function. Consequently, Blimp1 deficiency in Tregs under inflammatory conditions triggers CNS2 methylation, leads to Foxp3 downregulation, and drives a shift toward a pro-inflammatory T cell phenotype. SET domain-containing 2 (SETD2) is a type of histone methyltransferase that can catalyze lysine 36 trimethylation on histone 3 (H3K36me3) and has been recently reported to play an important role in the generation and function of different types of cells.– An animal study demonstrated that SETD2 sustains GATA3⁺ST2⁺ intestinal thymic-derived Treg (tTreg) cells by promoting GATA3 and ST2 expression and maintaining their reciprocal interaction. The SETD2-mediated regulation of GATA3 expression in Tregs is evolutionarily conserved between mice and humans and is crucial for the selective suppression of Th2 responses. Additionally, Setd2 modulates Treg cell promoters and intragenic enhancers, epigenetically regulating target gene transcription via H3K36me3-marked enhancers. However, the precise molecular mechanisms underlying this regulation remain elusive. Autoimmune diseases are prone to occur during Treg cell depletion therapy for tumors. Therefore, targeted identification of Treg cells in tumors is particularly important. Recently, a report reported that JMJD1C is a histone demethylase in the tumor microenvironment that regulates the adaptability of Treg cells in tumors but does not affect systemic immune homeostasis. JMJD1C deficiency enhances AKT and STAT3 signaling, leading to massive production of interferon-γ and a reduction in the number of tumor Treg cells. In addition to epigenetic regulation, other factors, including costimulatory signals, splicing factors, and ubiquitination modifications, also influence Foxp3 expression and function. Steroid nuclear receptor coactivator 2 (SRC2), a transcription coactivator, is crucial for Treg differentiation. SRC2 promotes Treg induction by upregulating Nr4a2, thereby facilitating immune tolerance., Recurrent somatic mutations in spliceosome factor 3b subunit 1 (SF3B1), particularly SF3B1-K700E, are frequently found in hematopoietic malignancies. Treg-specific expression of SF3B1-K700E leads to spontaneous autoimmune phenotypes. Mechanistically, SF3B1-K700E disrupts splicing, leading to reduced expression of Anapc13, a key regulator of cell proliferation. Restoring Anapc13 expression rescues Treg differentiation and restores their ability to prevent adoptive transfer-induced colitis. The E3 ubiquitin ligase ZFP91 promotes autophagy activation in Treg cells, supporting their metabolic programming and function. Mechanistically, upon TCR stimulation, ZFP91 quickly moves from the nucleus to the cytoplasm, where it mediates BECN1 ubiquitination, facilitating BECN1-PIK3C3 complex formation and enhancing TCR-induced autophagy activation and related downstream pathways. Moreover, Treg-specific loss of Rbx1, an E3 ligase with dual roles in neddylation and ubiquitylation through Cullin-RING ligases, induces severe inflammation by impairing key effector Treg functions and regulatory pathways. Similarly, Ube2m deletion in Treg cells, another neddylation-related enzyme, causes milder inflammation. In contrast, the loss of Rbx2/Sag or Ube2f, key components of the neddylation-CRL complex, has no significant impact. This finding underscores the distinct function of the Ube2m-Rbx1 axis in Treg regulation and suggests additional functions of Rbx1 beyond its interaction with Ube2m. RNF213, a RING finger protein, facilitates Treg differentiation and attenuates autoimmune disease via Foxo1 signaling. Mechanistically, it interacts with Foxo1, facilitating its nuclear translocation through K63-linked ubiquitination. Tumor microenvironment stressors induce the deubiquitinases Usp22 and Usp21, which are crucial for Treg cell fitness. Their deletion impairs Treg function and enhances antitumor immunity, highlighting Usp22 as a potential target for cancer therapy. The transcription factor BACH2 is expressed at elevated levels in resting Tregs, whereas its expression is diminished in activated Treg cells and during inflammatory responses. Within resting Tregs, BACH2 binds to the gene enhancer region that regulates activated Treg cell differentiation and inhibits TCR-driven activation of these genes by competing with AP-1 transcription factors for DNA-binding sites. This action of BACH2 helps maintain the resting state of resting Tregs and their long-term survival, which is necessary to maintain immune balance and achieve durable immunosuppression in cancer.

13Tregs are essential for maintaining immune balance, and their dysfunction or dysregulation can lead to a range of immune-related diseases. Understanding the role of Tregs in homeostasis and human diseases is critical for developing Treg-centered therapeutic strategies (Fig. 5).

14Within the spectrum of prevalent autoimmune conditions, rheumatoid arthritis (RA), type 1 diabetes (T1D), multiple sclerosis (MS), and systemic lupus erythematosus (SLE), Tregs are often dysfunctional or reduced in number, contributing to the breakdown of immune tolerance and the onset of disease. Understanding the complex interplay between Tregs and autoimmune diseases could elucidate ‌druggable targets‌ for novel therapeutic interventions for these immune dysregulation syndromes.

15In the context of RA, Tregs function as guardians of immune tolerance, suppressing excessive immune activation and inflammation. The imbalance between effector T cells and Tregs is considered crucial in RA pathogenesis.– Recent studies have demonstrated that CD8+ Tregs expressing Foxp3 can be stably generated in vitro via the use of TGF-β1 and rapamycin (RAPA). These TGF-β1/RAPA-induced human CD8⁺ Tregs exhibit robust suppressive function, characterized by high expression of Foxp3 and CD103. Notably, they significantly ameliorated collagen-induced arthritis (CIA) in mice, as evidenced by reduced clinical scores, decreased anti-collagen IgG levels, and diminished cartilage destruction. Additionally, Foxp3⁻CD8⁺ Tregs play non-redundant roles in autoimmune and infectious diseases by suppressing autoreactive CD4+ T cells, limiting tissue damage, and promoting the resolution of inflammation., Emerging evidence suggests that the function and number of Tregs are compromised in patients with RA., Studies have shown that RA patients exhibit reduced Treg frequencies, impaired suppressive function, and decreased CTLA-4 expression in peripheral blood and synovial fluid., Epigenetic modifications, including DNA methylation and histone deacetylation, further influence Treg differentiation and function in RA.,,, Clinical trials are assessing the effectiveness of adoptive transfer of ex vivo-expanded functional Tregs and Treg-stimulating agents such as IL-2 analogs and novel small molecules. A recent study explored the impact of inhibiting IL-6 signaling on various subpopulations of Tregs in RA, potentially improving patient prognosis. These innovative approaches seek to leverage the inherent regulatory capabilities of Tregs to restore immune homeostasis, alleviate RA symptoms, and potentially arrest the progression of the disease in human patients.

16In individuals with T1D, Tregs are often impaired or reduced in number, allowing autoreactive immune cells to attack and destroy β-cells. Recent studies highlight the crucial role of Tregs in T1D pathogenesis, with genome-wide association studies linking genetic susceptibility to immune cell function, particularly genes involved in Treg development and function., Functional studies in mouse models and peripheral blood analyses of T1D patients provide strong evidence of Treg dysfunction. Moreover, enhancing Treg function or increasing their population has been revealed to suppress or delay T1D onset, preserve β-cell mass, and maintain normoglycemia. These findings support the ongoing exploration of Treg-based therapies for T1D.

17The pathological hallmarks of MS include inflammation, demyelination, axonal damage, and gliosis. Self-reactive CD4⁺ T cells, especially Th1 and Th17 subsets, play crucial roles in triggering and maintaining the inflammatory cascade in MS. These T cells infiltrate the CNS and interact with resident immune cells, such as microglia and astrocytes, to promote demyelination and neurodegeneration. Additionally, the E3 ubiquitin ligase RNF213 is known to facilitate K63-type ubiquitination and nuclear import of Foxo1, thereby enhancing Treg cell development and mitigating autoimmune diseases such as MS. Current therapeutic strategies for MS aim to modify the disease course and reduce relapses. The most widely used drugs include interferon-β, glatiramer acetate, natalizumab, fingolimod, dimethyl fumarate, and teriflunomide. Emerging therapies targeting the immune system, such as B-cell depletion (ocrelizumab) and IL-2 receptor blockade (daclizumab), have shown promise in reducing relapses and slowing disease progression in some patients.– Ongoing research into the molecular mechanisms underlying MS pathogenesis, combined with advances in immunotherapies, shows potential for the development of innovative therapeutic approaches.

18Tregs play a pivotal role in maintaining immune tolerance and preventing autoreactive responses in SLE. Recent research on SLE has focused on understanding the underlying immunopathogenesis and developing novel therapies. For instance, CAR-T cell therapies targeting B cells, particularly anti-CD19 CAR-T cells, have shown promise in refractory SLE patients, as they result in B cell depletion and disease improvement., Moreover, the ability of IL-2 immunotherapy to selectively expand Tregs is being explored, and low-dose IL-2 can improve disease activity in SLE patients by expanding functional Treg subsets, which play crucial roles in maintaining immune tolerance. These therapies aim to restore immune homeostasis, reduce systemic inflammation, and improve the clinical outcomes of patients with SLE. Future research in SLE will likely focus on refining and optimizing CAR-Treg therapies.

19Compared with those found in peripheral blood and other tissues, the characteristics of Tregs in the TME are distinct. In blood and lymphoid tissues, Tregs typically maintain a relatively stable frequency, ranging from 5% to 10%. However, within tumors, they tend to accumulate and can account for more than 50% of all T cells., Many studies have shown that tumor-infiltrating Treg cells usually indicate a poor prognosis in most solid tumors, whereas in colorectal and endometrial cancers, the presence of Treg cells is linked to a better prognosis. However, several reports have suggested that increased Foxp3+ expression in colorectal cancer is associated with poor prognosis., These conflicting findings suggest that the role of Treg cells in colorectal cancer is context dependent and may vary on the basis of factors such as tumor stage, localization within the tumor microenvironment, or the presence of specific microbial or inflammatory signals.

20Tregs influence tumor growth, invasion, and metastasis in the TME. They express chemokine receptors (e.g., CCR4, CCR8, and CCR10), facilitating their recruitment to tumors., First, Tregs attenuate the antitumor activity of CD8+ T cells by competitively inhibiting CD28 co-stimulatory signaling through CTLA-4, depleting IL-2, and releasing adenosine., Second, they secrete immunosuppressive cytokines (IL-10 and TGF-β) and modulate the local immune state via metabolic pathways such as IDO, thereby creating an immunosuppressive environment., Third, Tregs also regulate the tumor immune microenvironment by suppressing various immune cells (conventional T cells, Teffs, B cells, NK cells, NKT cells, and monocytes), and promoting the accumulation of immunosuppressive cells such as M2 macrophages and myeloid-derived suppressor cells., The stability of Tregs is also influenced by the local environment. In the TME, factors such as hypoxia, metabolic changes (e.g., lactate accumulation), and pro-inflammatory or immunosuppressive cytokines (e.g., TGF-β and IL-10) enhance the immunosuppressive function of Tregs, promote their expansion, and maintain their stability. Additionally, tumor-associated macrophages (TAMs) in the TME facilitate Treg enrichment and the conversion of CD4⁺ T cells into Tregs by expressing molecules such as PD-L1 and IDO1. However, the plasticity of Tregs can also change under certain conditions. For example, under specific inflammatory conditions, some Tregs may lose their suppressive function and convert into effector T cells. Furthermore, VEGF and vascular regulatory mechanisms may affect the distribution and function of Tregs in the TME; therefore, TME-targeted strategies (such as IL-2 variants) are being explored to selectively enhance T effector cell function without activating Tregs.

21Tregs in hematological malignancies exhibit distinct characteristics and prognostic roles. Higher Treg levels indicate better outcomes in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) but worse prognoses in chronic lymphocytic leukemia (CLL), “activated B cell” (ABC) DLBCL, and “non-specific” (NOS) DLBCL. In CLL, increased Tregs correlate with advanced disease stage, high CD38 expression, and a shorter time to first treatment. Multiplex sequencing identified three Treg clusters, including an unconventional Foxp3-negative subset (high LAG3, CTLA4, and KLRB1). Activated Tregs have distinct gene expression patterns, including those of the TNFRSF4, TNFRSF18, and NF-κB pathway genes. Tregs are more abundant in the newly diagnosed and blast crisis phases of CML, potentially driving progression through immunomodulation. In the blood tumor microenvironment, Treg-derived IL-21 suppresses effector T cells and NK cells and regulates B cells, promoting immunosuppression. In AML, IL-21 reduces leukemia stem cell (LSC) self-renewal, promotes asymmetric division via p38-MAPK signaling, decreases LSC numbers, and improves survival in mice. It also serves as a prognostic biomarker and enhances treatment efficacy in vitro, while low-dose IL-21 prolongs AML survival. In mantle cell lymphoma (MCL), SOX11 expression is correlated with Treg infiltration and an immunosuppressive environment, potentially driving tumor progression. Tregs also express CD39/CD73, depleting ATP and generating adenosine, which exhausts effector T cells.,

22In summary, Tregs exhibit functional differences between solid and hematological tumors. In solid tumors, Tregs are primarily recruited through chemokine axes such as CCL28‒CCR10 and CCL22‒CCR4, whereas in hematologic malignancies, the CXCR4‒SDF1 axis facilitates Treg accumulation in the bone marrow or lymphoid tissues. Phenotypically, Tregs in solid tumors exhibit a tissue-resident profile characterized by high expression of Foxp3, CTLA-4, and CD39, whereas hematologic malignancies predominantly harbor circulating Tregs (Foxp3+CD25+), with some subsets exerting functions within the bone marrow microenvironment. The immunosuppressive strategies also differ, with solid tumor Tregs relying on cytokine-mediated suppression via TGF-β, IL-10, and IDO, whereas in hematologic malignancies, Tregs can directly inhibit B cells and NK cells or modulate myeloid cell differentiation. Functionally, solid tumor Tregs primarily contribute to immune evasion and the suppression of antitumor immunity, whereas in hematologic malignancies, they may influence the bone marrow microenvironment and promote leukemia stem cell survival.

23Newly discovered evidence indicates that Tregs are intricately involved in the development of T2D. Yuan et al. reported that the number of circulating Tregs was negatively correlated with fasting blood glucose concentrations in individuals with impaired glucose tolerance. The pro-inflammatory milieu in T2D is hypothesized to disrupt the Th17/Treg balance, favoring Th17 expansion and promoting chronic inflammation and metabolic dysfunction. Tregs are crucial regulators of glucose metabolism and insulin sensitivity., Notably, T2D patients exhibit reduced CD3⁺ T cells, suggesting a weakened immune response. Given their important role in immune regulation and metabolism, Tregs have emerged as promising treatment options for T2D. Research conducted by Liu et al. revealed that the infusion of Tregs enhanced insulin responsiveness and glucose tolerance in ob/ob mice, a commonly used model of T2D. Similarly, other studies have reported that treatment with the IL-2/anti-IL-2 complex, which expands Tregs in vivo, can ameliorate insulin resistance and glucose intolerance in animal models of T2D. These findings suggest that enhancing Treg function may represent a novel therapeutic approach for T2D.

24Chronic low-grade inflammation in adipose tissue, driven by immune cell infiltration, is a key driver of obesity-related metabolic disorders. The intricate interplay between the immune system and metabolic pathways under these conditions has garnered significant attention, particularly with respect to the role of Tregs. VAT-resident Treg cells have been shown to have a unique transcriptional profile, which is driven primarily by the nuclear receptor family member PPARγ. The accumulation of plasmacytoid dendritic cells (pDCs) and the subsequent production of IFN-α during obesity lead to the depletion of PPARγ+ VAT-Treg cells. Blocking the IFN-α pathway in obese mice was found to restore VAT-Treg cell levels and enhance insulin sensitivity, indicating a potential therapeutic target. In addition to their role in obesity, Treg cells also play a vital role in other metabolic tissues, including the liver and skeletal muscle. In the liver, Treg-exclusive long non-coding RNA (lncRNA) Altre preserves the immune–metabolic balance by regulating mitochondrial function and Treg survival. In skeletal muscle, exercise has been shown to activate Treg cells, contributing to muscle regeneration and repair. Muscle-resident Treg cells exhibit unique transcriptional profiles and express factors such as Foxp3 and amphiregulin, which promote tissue growth.

25Cardiovascular diseases (CVDs), encompassing conditions such as atherosclerosis and myocardial infarction, constitute the primary cause of death globally. The intricate interplay between immune system components and the cardiovascular system is crucial in the development of these conditions. Among immune cells, Tregs have emerged as critical modulators of immune homeostasis and inflammation, thereby influencing the progression and outcomes of CVDs.

26The role of the immune system, particularly Tregs, in the development and progression of atherosclerosis has been the subject of intensive research. Recent studies have shown that the number and function of Tregs are reduced in patients with atherosclerosis, suggesting their involvement in disease pathology. Reports indicate that the production of IL-17 by CD4+CD45RO+Foxp3+ T cells in the bloodstream is linked to atherosclerosis, suggesting that certain Treg subsets might exhibit pro-inflammatory properties under specific conditions, contributing to the complexity of Treg function in this disease. Tregs are emerging as promising therapeutic targets in atherosclerosis because of their ability to modulate immune-inflammatory pathways and stabilize plaques. Key molecules such as IL-10, TGF-β, and CTLA-4 mediate Treg-mediated suppression of pro-inflammatory cells, oxidative stress, and plaque progression. IL-35-producing Tregs further inhibit proatherogenic immune activation. By enhancing Treg function or numbers, novel therapies could attenuate vascular inflammation, promote tissue repair, and reduce atherosclerosis severity, offering a strategic shift toward immune regulation in cardiovascular disease management.,

27Myocardial infarction (MI), the most common form of acute heart injury, is a leading cause of mortality worldwide. Tregs migrate to infarcted hearts post-MI, suppressing inflammation and fibrosis by promoting macrophage repair phenotypes via anti-inflammatory factors (e.g., IL-10 and nidogen-1) and inhibiting damage to CD8+ T cells.– Preclinical studies have shown that exogenous Treg administration reduces cardiomyocyte death and fibrosis, improving cardiac function. Gene-modified Tregs may increase therapeutic stability, addressing challenges in post-MI repair., In addition, local treatment with Tregs significantly enhances tissue regeneration and wound healing in mouse models of skeletal, muscle, and skin injury. Tregs promote the switch of monocytes and macrophages to an anti-inflammatory state, particularly through the secretion of IL-10. Moreover, genetically modified Tregs are promising for addressing the challenges faced by conventional Treg cell therapies, such as maintaining long-term stability and efficacy, which are crucial for their application in post-MI heart repair. These results emphasize the importance of Tregs in facilitating heart regeneration and suggest their possible application as an innovative immunotherapy approach for MI.

28Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by motor neuron degeneration and inflammation, leading to respiratory paralysis and death., Treg cells are crucial in the pathogenesis of ALS. Tregs can suppress the pro-inflammatory responses of Teff cells and myeloid-derived cells, thereby providing protective effects in ALS patients., Consequently, numerous reports have proposed the use of Treg cells as a potential therapeutic strategy for ALS, and their neuroprotective effects have been further investigated in clinical studies. Solmaz et al. reported that increased effector T cells in the blood and cerebrospinal fluid of ALS patients correlate with poorer survival, whereas higher activated Treg levels and a greater activated-to-resting Treg ratio are linked to improved survival. Beers et al. demonstrated that the adoptive transfer of endogenous Tregs from early-stage mSOD1 mice into late-stage ALS disease model mice helped sustain the M2 microglial phenotype, thereby extending disease duration and improving survival outcomes in the recipients. Sheean et al. provided compelling evidence that the immune system regulates disease progression in ALS patients and highlighted the crucial role of Tregs in disease pathobiology. This study suggested that expanding peripheral Treg cells may have a beneficial effect on suppressing toxic neuroinflammation within the brains of ALS patients. IL-2 is essential for the survival and function of Tregs,– and Tregs are highly sensitive to low environmental levels of IL-2.– IL-2 therapy has been shown to restore the immunosuppressive function of Tregs in vitro., A clinical study (NCT04055623) reported the safety profile and protective role of combined Treg/IL2 treatments in ALS patients, and IL-2 administration has been proposed as a novel therapeutic strategy. The IMODALS study (NCT02059759) reported the pharmacodynamics and safety of low-dose (ld) IL-2, which demonstrated a significant increase in Treg cell numbers without any serious adverse events. However, researchers suspect that the molecular benefits linked to changes in Treg numbers merit further investigation. Notably, Giovannelli et al. conducted a subgroup analysis within the same IMODALS cohort via microarray gene expression profiling, identifying transcripts related to lipid metabolism that were associated with drug response. Overall, these data provide new evidence for the role of Treg cells in ALS disease progression and may offer a promising treatment option for patients with this disease.

29Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia., Effector T cells (Th1 and Th17) and Treg cells have been associated with AD.– CD4+ effector T cells expedite AD progression in APP/PS1 mice. Furthermore, early depletion of Tregs is linked to accelerated cognitive impairment, while restoring Tregs has been shown to improve cognitive function. Treg-mediated neuroprotection is widely recognized, but its therapeutic potential is limited by a lack of specific antigen targeting. Recently, researchers have engineered Tregs with Aβ-specific T cell receptors (TCR Aβ). These TCR Aβ-Tregs help clear Aβ deposits, shift effector cells toward a regulatory phenotype, and reduce neurotoxicity, showing promise in AD models., Scientists have created a lipid nanoparticle nanovaccine with Aβ peptides and rapamycin, effectively targeting dendritic cells to produce anti-Aβ antibodies and Aβ-specific Tregs, clear Aβ plaques in the brain, reduce neuroinflammation, and prevent cognitive decline in mice. These observations suggest that targeting Tregs is a promising therapeutic strategy for AD.

30Parkinson’s disease (PD) is the second most common neurodegenerative disease after AD and is expected to affect more than 1.2 million people by 2030.– Treg cells are crucial for limiting neurodegeneration in PD, as shown in animal models. The depletion of Tregs has been shown to exacerbate neuroinflammation in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD., Furthermore, Treg enhancement, induction, or transfer has been demonstrated to promote neuronal survival and reduce neuroinflammation in a PD mouse model,, highlighting their direct role in neuroprotection. Moreover, expanding dysfunctional Tregs isolated from PD patients, both in vivo and in vitro, successfully restored their suppressive function.– Tregs from patients with PD exhibit impaired abilities to suppress effector T cell functions. Moreover, adoptive transfer of Tregs has been demonstrated to confer greater than 90% protection to the nigrostriatal system in patients with PD. Tregs mitigate effector immune responses, uphold central and peripheral tolerance, and reduce neuroinflammation. In addition to being suppressed, they also redirect neurodestructive Th1 and Th17 responses toward neuroprotection. The loss of midbrain dopamine neurons (mDANs) leads to motor dysfunction in PD, making cell replacement a promising therapy.– However, the poor graft survival of mDANs hinders clinical success., Recent studies suggest that co-transplantation of mDAPs and Tregs modulates the host immune response triggered by surgery and significantly protects mDANs while inhibiting the proliferation of TH cells. This approach may enhance the effectiveness and safety of cell replacement therapy for PD and other neurodegenerative diseases. Taken together, these findings suggest that Treg cells may constitute a novel therapeutic option for patients with PD.

31Solid organ transplantation is crucial for end-stage organ failure, but immune rejection hinders graft success and long-term survival. Tregs can improve outcomes by reducing rejection and adverse effects. In kidney, liver, and heart transplants, increasing Treg quantity and function post-surgery is linked to lower rejection rates and better graft survival, highlighting their role in maintaining graft stability. Tregs reduce graft rejection in organ transplantation by inhibiting effector T cell activation, promoting immune tolerance, and reducing reliance on long-term immunosuppressants while limiting the expansion of allogeneic-specific T and B cells., Tregs create an immunosuppressive environment by reducing IL-2 consumption and side effects. Short-term IL-2/anti-IL-2 antibody pre-conditioning promotes long-term acceptance of mismatched lung allografts by inducing Tregs to form protective clusters, eliminating the need for continuous immunosuppression. CAR-Treg therapy, especially when combined with rapamycin, prolongs survival in heart transplants and reduces the need for long-term immunosuppression. Hence, Treg-based therapies, including ex vivo expansion and reinfusion, are under investigation. However, successful Treg engraftment requires creating a suitable environment, overcoming host Treg competition, and ensuring IL-2 and antigen availability. Future research with larger sample sizes and standardized methods is needed to fully evaluate the efficacy and safety of Tregs in solid organ transplantation and establish consistent clinical guidelines.

32Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment option for numerous types of cancers. Tregs can suppress GVHD without affecting the effect of graft-versus-leukemia (GVL), and a decrease in the number of Tregs is associated with an increase in the severity of GVHD., Interventions such as ultra-low doses of IL-2 or adoptive transfer of Tregs can increase the Treg-to-effector T cell ratio and improve GVHD outcomes in animal models. These methods have been evaluated in phase I clinical trials., Research shows that Tregs limit the expansion of Tconvs involved in GVHD by shifting their metabolism from glycolysis to oxidative phosphorylation, reducing GVHD severity without impacting the graft-versus-tumor effect. Careful attention to timing and the Treg-to-Tcon ratio is crucial in infusion therapy. In an immunodeficient non-obese diabetic/severe combined immunodeficient (NSG) mouse model of allogeneic hematopoietic stem cell transplantation, Allan Thiolat et al. studied two IL-2/anti-IL-2 complexes (IL-2Cxs) and their effects on GVHD, tumor recurrence, and immune cell function. Both complexes prevent GVHD and promote Treg expansion, but only IL-2/anti-IL-2Cx, which increases Tregs, reduces CD8⁺ T cell exhaustion and has strong antitumor effects. Furthermore, metabolism plays a pivotal and fundamental role in the differentiation processes of both T cells and Tregs: glycolysis drives GVHD in allogeneic T cells, whereas oxidative phosphorylation regulates Treg inhibitory function.

33As of March 2025, ClinicalTrials.gov has witnessed the registration of a significant number of clinical trials leveraging Treg cells as an intervention, with more than 260 items in total. These trials included all study statuses and span a diverse range of human diseases, highlighting the growing interest in exploring the potential of Treg cell therapy. Among them, a total of 84 clinical trials are related to transplantation, 74 are associated with tumor specificity, 60 are targeted at autoimmune diseases, 31 concern metabolic diseases, 19 are related to cardiovascular diseases, and 12 are associated with neurodegenerative diseases (Table 2). Furthermore, most clinical trials employing Treg cell therapy have opted for ex vivo-expanded polyclonal Tregs. In contrast, antigen-specific Tregs are preferentially located at antigen-presenting sites and exhibit stronger immunosuppressive effects than polyclonal T cells. Therefore, efforts have focused on the use of genetic engineering techniques to express recombinant TCRs or synthetic receptors to manipulate the antigen specificity of Tregs, which appear to be more promising and feasible approaches. The purpose of Treg cell therapy in autoimmune diseases is to restore immune tolerance and mitigate pathological immune responses. Transplantation aims to prevent graft rejection and manage GVHD. In cancer, the primary goal is to modulate the immunosuppressive microenvironment and enhance antitumor immunity. Overall, Treg cell therapy represents a fascinating and rapidly evolving area of research, with the potential to revolutionize the treatment of numerous human diseases by capitalizing on the unique properties of these regulatory immune cells.

34Blocking CD28/CTLA-4, PD-1, TIGIT and LAG-3 with monoclonal antibodies or activating CD25, GITR, ICOS, and OX40 can diminish the immunosuppressive function of Treg cells (Fig. 6). These approaches not only enhance antitumor immune responses but also hold therapeutic potential for managing autoimmune diseases, combating chronic viral infections, alleviating inflammatory conditions, and promoting anti-graft immune responses in transplantation settings. In autoimmune diseases, Treg cells often present functional abnormalities, and the immune balance is disrupted. Blocking the relevant targets mentioned above with monoclonal antibodies can weaken the abnormal immunosuppression of Tregs and appropriately regulate the function of effector T cells, which helps to rebalance the body’s immune state, reduce inflammation and damage, and relieve the condition of the disease.

35Tregs express immune checkpoints such as CTLA-4 and PD-1, suppressing immunity via ligand interactions with effector T cells. CTLA-4 blockade induces CD28-dependent hyperproliferation of Tregs in the TME, necessitating simultaneous Treg inactivation for tumor rejection. Disruption of this CTLA-4/CD28-dependent loop may reduce therapeutic benefits. Tregs also suppress T cells via CTLA-4-mediated trogocytosis, reducing CD80/CD86 expression. Combining CTLA-4 and PD-1/PD-L1 blockade enhances antitumor immunity. CTLA-4 also inhibits Treg glycolysis, and its blockade promotes glucose metabolism in tumors with low glycolytic activity. In mice, anti-CTLA-4 antibodies deplete TI-Tregs via Fc receptor interactions, although human Treg depletion remains debated. Ipilimumab depletes Tregs, whereas tremelimumab increases effector T cells without altering Treg levels. Both enhance intratumoral CD4+ and CD8+ infiltration, and Fc modifications may improve Treg depletion., Targeting OX40, CTLA-4, and GITR preferentially modulates intratumoral Tregs, especially in mouse models. Blocking CD28/CTLA-4 shows promise in autoimmune diseases, chronic viral infections, and transplantation. CTLA-4 regulates immune responses in MS and SLE. Abatacept, a CTLA-4 fusion protein, inhibits CD80/CD86-CD28 binding, reducing T cell activation in refractory rheumatoid arthritis, whereas belatacept improves kidney graft survival by blocking CD28 co-stimulation.

36PD-1 blockade can increase the number of suppressive Tregs in the TME, promoting tumor progression. In advanced gastric cancer, it enhances Treg function and is correlated with rapid progression. While PD-1 blockade boosts CD8+ T cell proliferation and cytokine production, its effectiveness depends on the CD8+ Teff-to-Treg balance. In highly glycolytic tumors such as MYC-amplified and liver cancers, Tregs show increased PD-1 expression. In low-glucose TMEs, Tregs absorb lactic acid via MCT1, which upregulates PD-1 by promoting NFAT1 translocation. αPD-1/PD-L1 treatment affects Tregs systemically, with tumor-draining lymph nodes crucial for response. Increased Treg activity post-treatment is linked to hyperprogression, and the pre-treatment PD-1 balance between CD8+ T cells and Tregs predicts efficacy. The PD-1 pathway plays diverse roles in Treg function, suggesting its therapeutic potential in autoimmune diseases. In transplantation, PD-1 maintains tolerance by limiting Teff activity and promoting Tregs, while its blockade may cause rejection. In GVHD, PD-1 inhibits donor T cells to reduce damage, but its blockade may exacerbate GVHD while enhancing antitumor immunity.,

37However, the mechanisms of these antibodies remain unclear. Differences in their effects may stem from differences in Treg numbers, genetic backgrounds, and immunotherapy timing. Overall, the effects of ICBs on Tregs are influenced by metabolic substrates, co-stimulatory signals, Fc receptor-expressing phagocytes, and the timing of analysis.,

38TIGIT has gained recognition as a potential therapeutic target in both autoimmune diseases and cancer. In conditions such as RA and SLE, where the immune system attacks the body, TIGIT regulates immune balance. Mouse models have shown that TIGIT deficiency or blockade leads to excessive T cell activation, inflammation, and increased autoimmune susceptibility, while activating TIGIT alleviates disease symptoms., Additionally, dexamethasone-loaded nanoparticles (IM-MNPs/DXM) targeting CD4+ T cells can regulate PD-1/TIGIT signals, suppress effector T cells, enhance Tregs, and reduce cytokine production. These nanoparticles show significant efficacy in treating lupus nephritis with few side effects, suggesting that they are promising treatment platforms.

39TIGIT is highly expressed on TI-Tregs, and targeting it with antibodies depletes TI-Tregs without affecting Tconvs, making it a promising immunotherapy target. In melanoma patients, Tregs exhibit increased TIGIT expression and a higher TIGIT/CD226 ratio, which is associated with a greater Treg frequency in tumors and a poor response to ICB therapy. Targeting both TIGIT and CD226 activation may counteract Treg suppression in solid tumors. TIGIT+ Tregs suppress Th1 and Th17 cells, whereas TIGIT-deficient Tregs enhance antitumor immunity. Additionally, the balance between PD-1 and TIGIT in Tconv cells is crucial for antitumor function. Ongoing clinical trials, including one combining tiragolumab (anti-TIGIT) with atezolizumab (anti-PD-L1) for non-small cell lung cancer, highlight the therapeutic potential of TIGIT. However, the failure of the Skyscraper 06 study (Link: Genentech: Press Releases) means that the combination therapy did not demonstrate the expected advantage in extending survival in individuals afflicted with non-squamous non-small cell lung cancer, although the overall safety profile was in line with that of previous studies. In addition to the failure of the Skyscraper 06 study, Roche’s other important study, the Skyscraper 02 of Tilacumab, a phase 3 clinical trial in extensive-stage small cell lung cancer (ES-SCLC), also failed to meet the primary endpoints of PFS and OS. These setbacks undoubtedly cast a shadow on the prospects for the development of TIGIT monoclonal antibodies. Nevertheless, other TIGIT monoclonal antibodies are still being evaluated in clinical trials for the treatment of refractory solid tumors, either alone or in combination with other drugs (such as those in trials with NCT numbers: NCT05706207, NCT05390528, NCT05102214, NCT05060432, NCT05329766, NCT05390528, and NCT04354246).

40LAG-3 and Treg cells form a complex, powerful immunosuppressive mechanism that aids tumor immune evasion and is associated with various diseases beyond cancer., LAG-3 is expressed primarily on B cells, NK cells, DCs, activated T cells, and Tregs. LAG-3 also suppresses Teff cell proliferation and cytokine production while promoting the expression of immunosuppressive factors such as IL-10 and TGF-β in Tregs., Blocking LAG-3 with monoclonal antibodies, such as relatlimab (combined with nivolumab as Opdualag), reduces Treg immunosuppressive functions and enhances T cell activation (NCT03470922). Additional clinical trials, such as NCT05352672, NCT01968109, NCT03459222, NCT05002569, and NCT04140500, are currently assessing the efficacy of anti-LAG-3 monoclonal antibodies in cancer treatment. Furthermore, combining LAG-3 blockade with PD-1/PD-L1 and CTLA-4 inhibition has shown promise in enhancing antitumor responses.

41Current research focuses on the role of LAG-3 in the tumor microenvironment, but its relationship with autoimmune diseases remains unclear. LAG-3 is critical for maintaining immune tolerance and may become a therapeutic target for autoimmune disorders. It plays a role in diseases such as T1D and MS, where it helps regulate Treg cells and prevents excessive immune activation. Reduced LAG-3 expression in autoimmune conditions such as relapsing-remitting MS and type 1 diabetes leads to dysregulated T cell responses, and enhancing LAG-3 activity could offer therapeutic potential. A GWAS meta-analysis linked 290 sequence variants to autoimmune thyroid disease (AITD), including a rare LAG3 variant (rs781745126-T) that reduces LAG-3 expression and is associated with AITD, vitiligo, and other T-cell-mediated diseases. This study suggested that LAG-3 deficiency or blockade enhances T cell activation and plaque inflammation in atherosclerosis, although its impact on lesion size needs further investigation in patients treated with LAG-3/PD-1 blocking antibodies for cardiovascular events.

42CD25, a component of IL-2R, is crucial for immune cell activation and is highly expressed in hematological malignancies such as leukemia and lymphoma. Targeting CD25 depletes Tregs, enhancing antitumor immunity. Modified IL-2 improves vascular leakage syndrome treatment by expanding cytotoxic T cells while reducing Tregs. Low-dose IL-2/CD25 in female NOD mice prevents the progression of pre-T1D and improves β-cell function after treatment cessation. It also enhances antitumor immunity by activating Tregs and increasing the number of effector T and NK cells. Additionally, mutant IL-2 and receptor-biased IL-2 are being explored for the treatment of autoimmune diseases and tumors in clinical trials. Roche’s RG6292, a non-blocking anti-CD25 antibody, selectively eliminates Tregs without affecting IL-2 signaling in Teff cells (NCT04158583), resulting in limited toxicity in animal models. Antibody‒drug conjugates such as ADCT-301, which target CD25, show enhanced safety and efficacy in treating CD25+ lymphoma, suggesting potential for clinical application. Further research should focus on targeted antibody activity at tumor sites and engineering approaches to improve efficacy and reduce toxicity.

43Targeting CD25 for cancer immunotherapy focuses on depleting Tregs, but its lower expression in solid tumors limits its effectiveness. Additionally, the therapeutic window for CD25-targeted immunotherapy is narrow because CD25 is not only a marker for Tregs but also a molecule upregulated on activated Teffs. Studying CD25-targeted drugs in CD25+ tumors requires a balance of binding affinities to both Tregs and Teffs for effective treatment, as Treg clearance is accompanied by Teff clearance. The dosage and timing of these drugs are also critical to treatment outcomes., Moreover, combining Fc-optimized anti-CD25 antibodies with anti-PD-1/PD-L1 antibodies has synergistic effects in the treatment of mouse tumor models.

44GITR, a co-stimulatory molecule on activated CD4+ and CD8+ T cells and Tregs, is a promising immunotherapy target because of its ability to enhance Teff function and counteract Treg suppression. In autoimmune diseases, it can suppress effector T cell activation and enhance Treg-mediated immune tolerance to reduce inflammation in diseases such as systemic lupus erythematosus and multiple sclerosis., However, in specific autoimmune disease models, such as EAT and EAE, anti-GITR antibodies can worsen disease.

45GITR activation increases IL-2, CD25, and interferon gamma production, leading to antitumor effects by reducing Foxp3+ Treg functions. The GITR agonist DTA-1 can reduce intra-tumoral Tregs by more than 50%., A phase 1 trial of the GITR agonist TRX518 (NCT01239134) revealed safe and immune effects in advanced cancer patients, reducing Tregs both systemically and within tumors but with limited clinical response. Preclinical studies suggest that combining GITR agonism with PD-1 blockade may rejuvenate T cells. This has prompted research on combining TRX518 with PD-1 pathway blockade for treating patients with advanced refractory tumors (NCT02628574). GITR has shown efficacy in mouse models but not in clinical trials, potentially owing to differences in GITR expression between humans and mice. GITR+CD4 T cells, including Tregs and Tconv cells, contribute to the immunosuppressive microenvironment in gastric cancer (GC), and their enrichment is linked to poorer prognosis. In addition, the cellular distribution of the GITR protein in Treg cells depends on the microenvironment. Preclinical studies have shown that combining GITR agonism with Fc-γ receptor-mediated Treg depletion increases the Teff: Treg ratio, leading to tumor shrinkage. Targeting GITR in Tregs with an αGITR antibody promotes their differentiation into effector T cells, reducing Treg-mediated suppression and boosting antitumor immunity in glioblastoma. Combined with αPD1 antibodies, this approach improves survival and may lead to complete tumor eradication, offering a promising treatment strategy.

46OX40 is a co-stimulatory molecule in the TNF superfamily that facilitates T cell activation via TCR stimulation and is expressed in multiple T cell subsets, including effector T cell and Tregs. Binding OX40 to its ligand increases the survival and expansion of Teff and memory T cells while reducing the immunosuppressive activity of Tregs. OX40 signaling is involved in the activity or recurrence of multiple autoimmune and inflammatory diseases, such as rheumatoid arthritis and myasthenia gravis., The OX40/OX40L axis also contributes to skin inflammation in diseases, including atopic dermatitis (AD), psoriasis, alopecia areata (AA), and pemphigus, making it a promising therapeutic target. The OX40 agonist OX86 induces Treg depletion in the TME and increases CD8+ Teff infiltration in a B16F10 melanoma model. OX40 co-stimulation counteracts Treg suppression and enhances T cell survival, proliferation, and effector functions. MEDI6383, a recombinant OX40L IgG4P Fc fusion protein, shows potent agonist activity, counters Treg suppression, enhances tumor-reactive T cell cytolytic activity, and reduces tumor growth in mice. OX40 agonists have demonstrated enhanced antitumor immune capabilities in various tumor models and are currently being explored as novel targets for cancer immunotherapy in clinical trials. The primary OX40 agonist antibodies used in clinical research include INCAGN01949, MEDI6469, BAT6026, PF04518600, and SL279252.– An innovative approach using nanoparticles loaded with an OX40L plasmid reprograms tumor cells into antigen-presenting cells, triggering T cell proliferation and antitumor responses without significant toxicity. While OX40 therapy shows promise in preclinical models, its clinical efficacy alone is moderate, but combining OX40 therapy with anti-PD-1/PD-L1 inhibitors has strong potential.

47ICOS belongs to the CTLA-4 family and is widely expressed in activated CD4+ T cells and CD4+ iTregs. It enhances T cell activation and proliferation by interacting with its ligand, ICOSL. ICOS expression is elevated in various autoimmune disorders, allergic conditions, and cancers. For example, ICOS⁺ Tregs are the key cells for preventing diabetes in pancreatic islets, and expanding these anti-inflammatory cells can effectively treat diabetes. ICOS⁺ regulatory T cells but not ICOS-deficient T cells can improve active colitis. Emerging evidence suggests that IL-35 secreted by ICOS⁺ Tregs can inhibit IL-17-related airway hyperresponsiveness, which acts synergistically in allergic asthma. However, intervention in the ICOS pathway at different time points during the course of asthma can lead to different outcomes. When drugs or other methods are used to disrupt ICOS signaling for treatment, attention should be given to the intervention time and a comprehensive understanding of the specific disease. Activation of the ICOS signaling pathway during tumor immunotherapy can enhance antitumor immune responses. The ICOS regulates the function of effector T cells, particularly by promoting the differentiation of Th1 and Th17 cells, thereby enhancing their ability to attack tumor cells. Research indicates that GC patients with a greater proportion of ICOS+ Tregs have a poorer prognosis, whereas patients with a lower proportion of ICOS+ Tregs tend to have a better prognosis. Moreover, studies have reported that ICOS+ Tregs are the primary immunosuppressive cells in the liver cancer microenvironment. Therapies that target ICOS, such as JTX-2011, KY1044, and GSK609 (NCT02904226, NCT03829501, and NCT02723955), are approved by the FDA or are being evaluated in clinical trials. Other studies have shown that the antagonist MEDI-570 and agonist JTX-2011 (vopratelimab) can reduce the frequency of intra-tumoral Tregs in mice without affecting the frequency of pTregs.

48Tumor and stromal cells promote the accumulation of Tregs, including CCL22-CCR4, CCL1-CCR8, and CCL28-CCR10, through chemokine‒receptor interactions. These interactions drive Treg migration in the tumor microenvironment. Antibody therapy is a strategy to prevent Treg infiltration. CCR4 is key for Treg homing to tumors and is influenced by BRAFV600E signaling in melanocytes. Mogamulizumab, an anti-CCR4 antibody, reduces CCR4+ Tregs, enhancing antitumor responses in cutaneous T-cell lymphoma. In the tumor microenvironment, CCL17 and CCL22 recruit Tregs via CCR4, promoting immune escape. Targeting CCR4 with an antagonist in Pan02 tumor-bearing mice blocked Treg invasion and boosted tumor immunity., Notably, tumors with low initial CCL17 and CCL22 levels presented increased expression of these chemokines and CCR4+ TI-Tregs when treated with anti-CTLA-4, and combined blockade of CTLA-4 and CCR4 significantly prevented tumor development. Monitoring CCL17/CCL22 levels is crucial to avoid the counterproductive effects of immunotherapies such as anti-CTLA-4. For example, blocking CCL1, CCL22, CCR4, and CCR8 can prevent Treg migration.

49CCR8 appears to be non-essential for TI-Treg migration, as CCR8-deficient Tregs have similar tumor invasion rates to wild-type Tregs. Although there is no immunosuppressive effect, CCR8 binds to CCL1 to promote Foxp3 transcription and enhances the stability of TI-Tregs. Anti-CCR8 combined with anti-PD-1 therapy has synergistic effects, although caution is needed, especially in atherosclerotic plaques. In breast cancer, tumor-resident Tregs upregulate CCR8, making CCR8 targeting a promising immunotherapy strategy. IPG7236, a selective CCR8 antagonist, has strong anticancer effects, modulates Tregs and cytotoxic T cells, and significantly suppresses tumors in a breast cancer mouse model, both alone and with anti-PD-1. The CCL28-CCR10 system is less prominent in TI-Tregs but plays a significant role in ovarian cancer, where CCR10+ TI-Tregs respond to hypoxia-induced CCL28 and secrete VEGFA to increase immune tolerance and angiogenesis. In colorectal cancer, CCL28 overexpression is correlated with poor prognosis, as its interaction with CCR10 recruits Tregs, promoting tumor progression, indicating that removing CCR10+ Tregs from the TME could be a potential treatment for colorectal cancer.

50Epigenetic modifications such as histone and DNA methylation, acetylation, and ubiquitination regulate Foxp3 expression and the transcriptional profile of Tregs. Researchers are investigating epigenetic modifications to selectively modulate Treg function, converting them into cells with lower suppressive or even pro-inflammatory properties rather than depleting Tregs. This approach aims to harness the immunoregulatory properties of Tregs while mitigating their negative effects on antitumor immune responses.

51UHRF1, a DNMT adapter protein, is a potential therapeutic target; its deficiency enhances iTreg function in colitis, whereas its overexpression may impair Tfh cell differentiation, potentially contributing to systemic lupus erythematosus. EZH2, a PRC2 catalytic subunit with H3K27me3 activity, is upregulated in Tregs upon CD28 costimulation and is essential for immune tolerance. Its inhibition suppresses Tregs, enhancing antitumor immunity, whereas its activation promotes tolerance in autoimmune and transplant settings., Disruption of EZH2 shifts TI-Tregs to a pro-inflammatory state, increasing Teff activity and remodeling the TME. In combination with CTLA-4 blockade, EZH2 inhibitors enhance antitumor responses. Clinical trials are exploring the combination of the EZH2 inhibitor tazemetostat with ICB for lymphomas and solid tumors (NCT05152459, NCT04762160). The 18 types of histone deacetylases (HDACs), which are classified into five classes, regulate Foxp3 expression. HDAC9 is crucial for Foxp3 inhibition, whereas class I HDAC inhibitors (HDAC1, HDAC3, and HDAC8) modulate Treg function., For example, entinostat reduces Foxp3 expression, suppresses Treg activity, and enhances anticancer therapy via STAT3 activation. Inhibiting HDAC11 increases OX40L expression in Hodgkin lymphoma cells, shifting cytokine secretion to promote Th1/Th17 responses. Class IIa HDACs act primarily through protein interactions and can be targeted to disrupt Foxp3+ Treg function, enhancing anticancer immunity. The HDACi STR-V-53 shows promise in hepatocellular cancer treatment when combined with sorafenib or anti-PD1 therapy. HDAC inhibitors can also promote Treg production and tolerance, suggesting therapeutic potential for inflammatory diseases and organ transplantation. CBP/p300 regulates Treg differentiation by modulating pro-inflammatory cytokine secretion. During pTreg development, p300 inhibition blocks TGF-β-mediated CNS1 acetylation without affecting Foxp3 promoter acetylation. In murine models of lung cancer and mesothelioma, p300 inhibition reduces the number of intra-tumoral Tregs and enhances T cell infiltration, promoting anticancer immunity. GNAT family members (GCN5 and PCAF) also influence Treg function and antitumor immunity through partially unique and partially overlapping mechanisms. Additionally, histone acetyltransferases from the GNAT family differ from previously described Treg histone acetyltransferases (such as CBP, Tip60, and p300) in regulating Treg function and may be valuable therapeutic targets in immunooncology. Selective demethylation of the Treg-specific region stabilizes Foxp3 expression, and CNS2/STAT5 signaling promotes Treg stability, ensuring lineage identity in response to IL-2. CNS3, as an epigenetic switch, regulates the epigenetic state of the Foxp3 promoter, ensuring that precursor cells differentiate into Tregs in response to TCR stimulation.

52Currently, promising approaches in Treg cell research include redirecting T cells through chimeric antigen receptor (CAR) constructs for reprogramming and utilizing CRISPR-Cas9 technology to edit Treg genes., Future Treg cell therapies will benefit from advancements in immuno-oncology, especially CAR T-cell therapy, with over 1,520 clinical trials conducted globally (ClinicalTrials.gov). Unlike TCR Tregs, CAR-Tregs function independently of MHC and have a reduced reliance on IL-2, maintaining their phenotype while exhibiting stronger suppressive efficacy and enhanced tissue-homing capabilities., The key advantage of CAR-Tregs over CAR-T cells lies in their immunomodulatory effects, particularly in controlling overactive immune responses, thus offering safer treatment by reducing immunosuppression and inflammation, such as cytokine release syndrome. CAR-Treg cells expressing Foxp3+CD25High maintain a Treg-specific gene expression program with low cytotoxic potential and expand inversely to CAR-T cell proliferation in vivo, independent of tumor burden. Increased CAR-Treg levels in patients who fail CAR T-cell therapy hinder CAR-T cell expansion and contribute to late relapse. Modulating CAR-Treg cells may enhance antitumor effects or reduce neurotoxicity. New applications for CAR-Tregs are emerging, including B cell-targeting antibody receptor Tregs (BAR Tregs), which regulate FVIII-specific B cells to prevent or reduce anti-FVIII antibody production. Additionally, alloantigen-specific CAR Tregs targeting HLA-A2 significantly prolong heart transplant survival in mice, with enhanced efficacy when combined with rapamycin, suggesting the potential for reducing long-term immunosuppression in organ transplantation.

53The next generation of Treg cell engineering utilizes synthetic biology, offering systems such as T-cell antigen couplers, optimized CARs for soluble ligands, and the SUPRA CAR system to enhance specificity and address challenges such as tonic signaling and exhaustion. The SUPRA CAR requires multiple targets for activation, making it ideal for targeting tissue-specific antigens and solid tumors. In addition to oncology, CAR-Treg therapy shows promise for treating autoimmune, and chronic inflammatory diseases, such as asthma, T1D, and MS. By refining CAR design for specificity, persistence, and safety, CAR-Treg therapy is advancing precision immunotherapy. In the future, CAR-Tregs are being developed with three functional domains, namely, sensing, activation, and effector functions, enhancing their capabilities beyond those of classical Tregs. Optimizing Treg cell engineering involves identifying signaling pathways that, when integrated into CAR-like receptors, ensure the stability, survival, and suppressive function of antigen-specific Tregs. Progress also depends on selecting the best targets, such as inflamed tissues, pathogenic T cells, or antigen-presenting cells. Strategies that target soluble antigens and combine CAR-Tregs with other therapies or chemotherapies should also be explored for enhanced efficacy.

54CRISPR-Cas9 enhances T cell function and enables precise therapeutic interventions by targeting oncogenes, tumor suppressors, and Tregs. It restores Treg accumulation in obesity by modifying IFNαr1 signaling and increases the number of Tregs to reduce GVHD in leukemia transplants. In cancer, CRISPR suppresses Treg-mediated inhibition, boosting immunity, whereas in autoimmune diseases, it enhances Treg activity to curb inflammation.

55CRISPR-Cas9 can be used in several ways to edit Treg cells for various diseases. First, gene knockout, in which specific genes (e.g., Foxp3, IL-34, HO-1, BATF)– are knocked out in Treg cells, enhances tumor suppression, increases inflammatory sensitivity, and promotes cell death under oxidative stress. For example, knocking out TGFBR2 in Mesothelin CAR-T cells increases IFN-γ and IL-2 production, inhibits Foxp3 upregulation, and improves tumor elimination in vivo., Knocking out Rag-2 in mouse Tregs enhances the antitumor effect of PD-1 inhibitors in triple-negative breast cancer. Second, gene modification: CRISPR-Cas9 can modify genes in Tregs to enhance antitumor function. This includes altering Treg recognition of tumor antigens or engineering them to secrete cytokines such as IL-2 to support effector T cells. Third, genome editing: CRISPR-Cas9 can edit the entire genome of Tregs to modulate their immunosuppressive functions and insert specific antigen receptors to enhance antitumor responses. Engineered Tregs, combined with advancements in hypoimmunogenic human pluripotent stem cells, show significant antitumor effects and have the potential to revolutionize Treg cell therapy.

56Efforts to improve CRISPR-Cas9 technology focus on reducing off-target effects and genomic alterations by engineering high-fidelity Cas9 versions and exploring alternative CRISPR‒Cas systems. CRISPR now extends beyond genome editing to include gene activation, DNA methylation, and RNA editing. This technology enables precise knock-in of antigen receptors and editing of genes regulating Treg function., Recent advancements, such as the use of polymer-stabilized Cas9 nanoparticles and modified repair templates, have improved editing efficiency and reduced toxicity, increasing success across various cell types., CRISPR screens are also used to identify gene pathways that regulate Foxp3 expression in Tregs. Combining CRISPR–Cas9 with high-throughput technologies and bioinformatics is crucial for optimizing Treg cell therapies and achieving immune tolerance in autoimmune diseases.

57IL-2 is a pleiotropic cytokine that regulates immune homeostasis by balancing Teffs, NK cells, and Tregs. High-dose IL-2 enhances antitumor immunity but induces inflammation, whereas low-dose IL-2 selectively expands Tregs, promoting immune tolerance. To balance these responses, low-dose IL-2 and IL-2 derivatives have been developed to preferentially expand Tregs, promoting immune tolerance while minimizing off-target immune activation. Owing to the high-affinity expression of IL-2 receptors (CD25) on Tregs, low-dose IL-2 can selectively expand Tregs, showing promising potential in the treatment of various diseases, including autoimmune diseases (such as SLE, T1D, primary biliary cholangitis, and ulcerative colitis), as well as certain skin conditions (such as alopecia areata and psoriatic arthritis), and improving clinical symptoms. However, the efficacy and safety of this treatment depend on precise dose adjustments to avoid adverse effects on effector T and NK cells; furthermore, its use in solid organ transplants has not been well studied. IL-2 derivatives are designed to optimize bioactivity, half-life, selectivity, and safety, primarily for Treg expansion, Teff suppression, and improved pharmacokinetics. Bempegaldesleukin (NKTR-214), a PEGylated IL-2 derivative, preferentially activates CD122, promoting CD8+ T and NK cell expansion while limiting intratumoral Tregs, making it promising for tumor microenvironment modulation., IL-2/JES6 complexes and the single-chain hIL-2/F5111 fusion protein (F5111 IC) selectively expand Tregs, enhancing allograft tolerance and autoimmune therapy. Additionally, the mRNA-encoded IL-2 mutein (HSA-IL2m) expands Tregs and mitigates autoimmune disease in preclinical models, highlighting the potential of mRNA-based IL-2 immunotherapy.

58Moreover, the combination of nanocarriers and IL-2 provides a precise and efficient regulatory strategy for autoimmune diseases, gene therapy, and immune tolerance induction. Encapsulating IL-2 in nanoparticles or conjugating it to Treg-targeting molecules enhances its selective delivery, promoting Treg expansion, stability, and function, thereby improving immune regulation. This strategy has been validated across various nanoparticle platforms, including PLGA nanoparticles, ImmTOR nanoparticles, and AuNRs. These nanomaterials enable sustained IL-2 release, prevent non-specific activation of effector T cells, and enhance antigen-specific Treg expansion and functional durability while reducing dosage requirements and minimizing side effects.

59The gut microbiome influences the function of Tregs, thereby affecting various immune-related diseases. By modifying the gut microbiota through dietary changes or fecal microbiota transplantation, Treg activity can be indirectly enhanced. This not only boosts antitumor immunity but also may improve the immune balance in autoimmune diseases, metabolic disorders, allergic reactions, cardiovascular diseases, etc.– Studies have shown that alterations in the gut microbiota affect the Th17/Treg balance, influencing inflammatory bowel disease and myasthenia gravis., Modulating the gut microbiome enhances anti-PD-L1 efficacy by influencing Treg activity. Sivan et al. reported that Bifidobacterium strains increase antitumor immunity and improve the anti-PD-L1 response. Specific gut bacteria also impact anti-PD-1 therapy in metastatic melanoma by regulating Treg function.

60Cancer immunotherapy approaches, including CTLA-4 and PD-1 blockade, often lead to the depletion of Treg cells throughout the body, accompanied by a series of side effects, such as significant autoimmune complications.– Enhancing Treg function may be a therapeutic strategy to address this issue. As regulators of the immune system, Treg cells suppress excessive immune responses and contribute to the maintenance of immune homeostasis. Several approaches can be taken to enhance Treg cell function: (1) First, through specific drugs or treatment methods, Treg cells can be selectively activated or expanded, enabling them to exert stronger immune regulatory effects in the TME. Drugs, including the mTOR inhibitor rapamycin, as well as biological agents, such as IL-10, low-dose IL-2, and peptide, have been investigated for their potential in this regard.– (2) Modulating the signaling pathways of Treg cells: By conducting in-depth research into the signal transduction mechanisms of Treg cells, we can identify key molecules or pathways that affect their function. By regulating these signaling pathways, we can precisely control the function of Treg cells and enable them to play a more active role in tumor immunotherapy. (3) In combination with other immunotherapy methods, by combining Treg cell enhancement strategies with other immunotherapy methods, such as antibody and cell therapies, synergistic effects can be achieved, improving treatment outcomes. In Treg cell therapy, the administration of Treg cells can restore immune tolerance by rectifying the Treg imbalance and directly increasing the number of Treg cells, thereby enhancing immune suppression. Overall, it is crucial to closely monitor potential side effects and complications during the treatment process and make timely adjustments and interventions. With further research and technological advancements, we believe that more effective treatment strategies will emerge in the future, resulting in better treatment outcomes and an improved quality of life for patients with cancer (Fig. 7).

61Typically, Treg cells are crucial for preserving immune tolerance and ensuring overall immune homeostasis. This overview systematically summarizes the characteristics, classification, function, and mechanism of Treg cells as well as Treg-targeting approaches in cancer immunotherapy. Tregs possess unique characteristics and functions to regulate immune responses through a series of complex mechanisms, including direct contact with other immune cells, secretion of inhibitory cytokines, and modulation of antigen presentation., These features endow Tregs with tremendous potential for the treatment of various diseases, especially in cancer immunotherapy. Currently, Treg cell research is exploring promising avenues, such as the following: (1) Treg cell therapies, such as engineered IL-2 formulations, improving the specificity of Treg-targeted interventions, which are being explored to treat autoimmune diseases, transplant rejection, and certain cancers by modulating immune tolerance and preventing excessive immune responses. These therapies aim to enhance graft survival and reduce inflammation without compromising immune defense; (2) Reprogramming T cells through CAR constructs, which involves redirecting them and editing the genes of Tregs via CRISPR-Cas9 technology; (3) Deleting or reducing Tregs in the tumor microenvironment can boost antitumor immunity, which can be achieved via monoclonal antibodies targeting Treg markers such as CTLA-4, PD-1, TIGIT, and CD25, and the immune checkpoint molecules OX40, GITR, and ICOS; and (4) Tumor and stromal cells secrete chemokines, promoting Treg accumulation at the tumor site via interactions such as CCL22‒CCR4, CCL1‒CCR8, and CCL28‒CCR10. Antibody therapy is a strategy to prevent Treg infiltration in the tumor microenvironment. (5) Epigenetic processes, including histone methylation, acetylation, ubiquitination, and DNA methylation, also target Treg function by controlling the expression of Foxp3. (6) Other pathways, such as lipid oxidation or the gut microbiome, can affect Treg activity and enhance antitumor immunity. With respect to their functions and mechanisms, Tregs perform mainly immunomodulatory functions by inhibiting the stimulation and proliferation of effector T cells and increasing the production of anti-inflammatory factors. Tregs perform these functions through various mechanisms, including cell‒cell contact inhibition, cytokine‒mediated inhibition, and metabolic intervention., These mechanisms collectively ensure the crucial role of Tregs in maintaining immune balance and preventing autoimmune diseases. Importantly, the role of Tregs in tumor immunotherapy is complex and context dependent. The analysis and identification of specific Treg subsets related to immunosuppression and therapeutic responses can guide personalized immunotherapy strategies. Understanding the heterogeneity and functional characteristics of Tregs in individual patients may help tailor treatment plans to improve therapeutic outcomes.

62Although Treg cell therapy has immense potential, it has certain limitations. First, alterations in the number and functionality of Treg cells can result in the development of autoimmune diseases. In patients with untreated multiple sclerosis, active systemic lupus erythematosus, and active Crohn’s disease, the number of Treg cells is notably decreased, and their functionality is compromised. This reduces the efficiency of Treg cells in regulating immune responses, potentially contributing to excessive immune reactions and immune escape, which in turn affects treatment outcomes. Second, the simple infusion of autologous Treg cells often fails to achieve the desired therapeutic effect. Although Treg cells have immunosuppressive properties and can regulate immune responses, in some cases, functional disorders of Treg cells in patients may already occur, rendering them unable to effectively exert their effects. Additionally, although stimulating polyclonal Treg cells with antigen-presenting cells to obtain disease-related antigen-specific Treg cells is feasible, it is expensive, complex, and may yield insufficient cell numbers. Furthermore, in tumor therapy, Treg cells may increase the degree of immune evasion of tumor cells. Hence, the management and surveillance of Treg cell function in tumor therapy has emerged as a pivotal concern. To overcome these limitations, further research is needed to delve deeper into the biological characteristics and functional mechanisms of Treg cells, as well as to optimize treatment methods to improve therapeutic outcomes and reduce side effects.

63We envision several exciting avenues for future research. For instance, gaining profound insights into the mechanisms governing Treg cell function and malfunction in autoimmune diseases is essential. Moreover, the optimization of Treg cell isolation, expansion, and delivery methods is essential. Advances in cell culture techniques and biomanufacturing processes can help overcome the challenges associated with obtaining sufficient numbers of functional Treg cells. Additionally, the development of novel delivery systems, such as encapsulation in biodegradable scaffolds or the use of cell-penetrating peptides, can enhance the efficiency of Treg cell engraftment and function in vivo. Future studies should concentrate on identifying the elements that control Treg cell count and activity, facilitating the development of specific approaches to rejuvenate or boost their inhibitory functions. In conclusion, despite these challenges, Treg cell therapy presents a promising future with the potential to significantly improve treatment effectiveness and safety.